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to the possibility of a peripherin/RDS mutation at codon
172.
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Cystic Fibrosis Transmembrane-Conductance
Regulator Mutations among African Americans
To the Editor:
Cystic fibrosis (CF) is less common in African Americans
than in Caucasians of northern European descent, with
an estimated incidence of 1/15,300 (Hamosh et al., in
press), although the severity of the disease is comparable
across racial lines. Macek et al. (1997) recently reported
in the Journal the identification of several CF transmem-
brane conductance regulator (CFTR) mutations of note-
worthy prevalence in blacks. This information will help
clinical laboratories to improve the sensitivity of CF mu-
tation testing for African American patients.
We have identified a CFTR mutation in exon 7 in two
unrelated individuals of African American descent who
were not included in the study by Macek et al. The
mutation, DF311, results in the loss of a phenylalanine
residue in the fifth transmembrane domain of the CFTR
protein. One of our patients is a 4-year-old African
American female who presented, at age 7 mo, with hy-
pochloremic metabolic alkalosis and dehydration. She
was subsequently found to have sweat chloride values
on two occasions of 75 and 83 mEq/liter. Her lung dis-
ease is mild, with only slight peribronchial thickening
on chest x-ray, and she had Staphylococcus aureus in
her sputum at age 3 years. She is considered pancreatic
sufficient, on the basis of qualitative fecal fat analysis.
Without pancreatic-enzyme supplementation, she has
maintained a normal growth pattern, with height and
weight at the 50th percentile. Mutation testing deter-
mined her genotype to be DF508/DF311. The DF311
allele was first detected by the appearance of a distinct
heteroduplex pattern when PCR product encompassing
exon 7 was electrophoresed on 10% polyacrylamide.
The mutation was identified as DF311 by dideoxy se-
quencing. No additional DF311 alleles have been found
after a screening of a further 271 patient samples (˜8.5%
African American) at the University of North Carolina
in Chapel Hill.
The second patient was referred for genetic testing
because of abnormal fetal ultrasound findings. The pa-
tient was a 25-year-old (G2 P0 SAB1) African American.
An ultrasound performed at 17 wk gestation identified
a fetus with a Dandy-Walker malformation and an ech-
ogenic bowel. Follow-up ultrasound at 18.2 wk gesta-
tion confirmed the CNS abnormalities and a grade II
echogenic bowel. The patient was counseled with regard
to the numerous causes of Dandy-Walker malforma-
tions, as well as with regard to the causes of echogenic
bowel, including CF. The fetal karyotype was normal,
but maternal and fetal CF testing identified a hetero-
duplex pattern identical to the DF311 heterozygote pos-
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itive control (Mutation Detection Enhancement gel sys-
tem; FMC BioProducts). Patient DNA mixed with equal
amounts of DF311 control DNA showed the same het-
eroduplex pattern as did either the patient DNA sample
or the DF311 heterozygote DNA sample alone, sug-
gesting that these abnormal alleles were identical. DNA
sequencing using the ABI 377 nucleic acid sequencer
subsequently confirmed this sequence change to be the
DF311 mutation in heterozygous form.
Maternal cell contamination was ruled out by MCT-
118 genotyping. The father of the fetus was not available
for testing, and no other CF mutation or abnormal het-
eroduplex pattern was detected in the fetal sample. Be-
cause of the presence of the Dandy-Walker malforma-
tion, and prior to the CF results being provided to the
patient, the patient elected to terminate the pregnancy.
An autopsy was not performed, and fetal tissue was not
available for confirmation of the amniocentesis results.
DF311 was first reported in a 2-year-old boy with a
positive albumin-meconium test at birth and with re-
peatedly elevated sweat tests by age 4 mo (Meitinger et
al. 1993). His other mutation is DF508. Prophylactic
treatment with both pancreatic enzymes and mucolytic
agents to deter lung disease has prevented the onset of
either pulmonary or pancreatic symptoms in his first 6
years. The authors of that study did not identify any
other individuals with this mutation, after screening an
additional 205 CF chromosomes by SSCP (T. Meitinger,
personal communication). This patient is of Bavarian
Caucasian descent, and his pancreatic disease is distinct
from that of the patient seen at the University of North
Carolina in Chapel Hill (UNC), obscuring any corre-
lation between DF311 and a particular phenotype. Ap-
parent clinical dissimilarities among these three patients
might be attributable to undefined aspects of either the
genetic background or the environment, but low num-
bers prevent the drawing of conclusions along racial or
other lines. Interestingly, the two individuals whom we
describe, as well as the index case, each harbor a distinct
DF311-associated haplotype (1 1 2, 1 2 2, and 2 1 2)
defined by the flanking markers, XV2c-KM19-J3.11,
suggesting that this mutation has occurred more than
once. The multiple origins of DF311 suggest that it might
be found on additional chromosomes, but this would
not be limited to African American patients.
DF311 has thus been identified in two individuals of
African American ancestry. In this racial group, this mu-
tation appears to be more common than any CFTR mu-
tation except DF508, compared with other alleles also
identified in Caucasians. Among the 23 African Amer-
ican CF patients genotyped at UNC, the inclusion of
DF311 increased total mutation-detection rates by ˜2%.
On the basis of the criteria established by Macek et al.,
we feel that molecular diagnostic laboratories should
consider the inclusion of DF311 in the development of
CF mutation-testing panels tailored to African
Americans.
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mtDNA Mutations That Cause Optic Neuropathy:
How Do We Know?
To the Editor:
Leber hereditary optic neuropathy (LHON) is an inher-
ited form of bilateral optic atrophy in which the primary
etiological factor is a mutation in the mitochondrial ge-
nome (mtDNA) (reviewed in Johns 1994; Riordan-Eva
et al. 1995; Nikoskelainen et al. 1996; Howell 1997).
Wallace et al. (1988) were the first group to identify a
LHON mutation, when they showed that a high pro-
portion of LHON families carried a mutation, at nucle-
otide 11778, that results in the substitution of histidine
for the highly conserved arginine at amino acid po-
sition 340 of the ND4 subunit of complex I
(NADH–ubiquinone oxidoreductase). The 11778 mu-
tation is found in 50%–70% of all LHON pedigrees
(e.g., see Mackey et al. 1996). Since the study by Wallace
et al. (1988), hundreds of LHON patients from around
